E Crocetti1,2, I Stanganelli3,4, S Mancini1, R Vattiato1, O Giuliani1, A Ravaioli1, C Balducci1, F Falcini1,5, N Pimpinelli2. 1. Romagna Cancer Registry, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy. 2. Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy. 3. Skin Cancer Unit, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy. 4. University of Parma, Parma, Italy. 5. Romagna Local Health Unit, Forlì, Italy.
Abstract
BACKGROUND: The 8th edition of TNM has introduced new rules for staging cutaneous melanoma. OBJECTIVE: To compare TNM 7th and 8th editions in defining pathological stages of melanoma. METHODS: A population-based series of 1847 skin melanoma from Romagna cancer registry (Italy) incident during 2003-2012 has been used to measure the agreement (with Cohen's kappa) between TNM 8th and 7th editions in defining melanoma stage. Disease-specific survival has been computed for each stage according to TNM 7th and 8th. RESULTS: The agreement between the two TNM editions was quite good when considered on average (kappa = 70.7%), moderate for stage I (61.5%), nearly perfect for stage II (95.0%), but extremely poor for stage III (8.1%). The overall melanoma-specific observed survival was 90.8% at 5 year and 88.9% at 10 year with a strong prognostic effect of stage. CONCLUSION: TNM 8th edition introduces several changes which do not seem really helpful in addressing the care of stage I melanoma and may complicate the definition and comparability of stage III.
BACKGROUND: The 8th edition of TNM has introduced new rules for staging cutaneous melanoma. OBJECTIVE: To compare TNM 7th and 8th editions in defining pathological stages of melanoma. METHODS: A population-based series of 1847 skin melanoma from Romagna cancer registry (Italy) incident during 2003-2012 has been used to measure the agreement (with Cohen's kappa) between TNM 8th and 7th editions in defining melanoma stage. Disease-specific survival has been computed for each stage according to TNM 7th and 8th. RESULTS: The agreement between the two TNM editions was quite good when considered on average (kappa = 70.7%), moderate for stage I (61.5%), nearly perfect for stage II (95.0%), but extremely poor for stage III (8.1%). The overall melanoma-specific observed survival was 90.8% at 5 year and 88.9% at 10 year with a strong prognostic effect of stage. CONCLUSION:TNM 8th edition introduces several changes which do not seem really helpful in addressing the care of stage I melanoma and may complicate the definition and comparability of stage III.
Authors: Matthew C Hynes; Paul Nguyen; Patti A Groome; Yuka Asai; Meaghan E Mavor; Tara D Baetz; Timothy P Hanna Journal: BMC Cancer Date: 2022-07-01 Impact factor: 4.638
Authors: Claus Garbe; Ulrike Keim; Stefan Suciu; Teresa Amaral; Thomas K Eigentler; Anja Gesierich; Axel Hauschild; Lucie Heinzerling; Felix Kiecker; Dirk Schadendorf; Rudolf Stadler; Cord Sunderkötter; Thomas Tüting; Jochen Utikal; Uwe Wollina; Christos C Zouboulis; Ulrich Keilholz; Alessandro Testori; Peter Martus; Ulrike Leiter; Alexander M M Eggermont Journal: J Clin Oncol Date: 2020-06-12 Impact factor: 44.544